A Review of Leukofiltration Therapy for Decreasing the Morbidity Associated with Cardiopulmonary Bypass and Acute Inflammatory Bowel Disease

Ortolano, Girolamo A.; Capetandes, A.; Wenz, Barry

doi:10.1046/j.1526-0968.2002.00338.x

Cited by 7 publications

(12 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ortolano et al. concluded that 76% of 115 patients with inflammatory bowel disease treated with LCAP showed remission that did not require corticosteroid or cytoablative support for maintenance (8). However, detailed mechanisms underlying the therapeutic effects of LCAP remain unclear.…”

mentioning

confidence: 99%

Mobilization of Bone Marrow Cells by Leukocytapheresis in Patients With Ulcerative Colitis

et al. 2008

View full text Add to dashboard Cite

While several trials have suggested that leukocytapheresis by filtration can benefit patients with active ulcerative colitis (UC), mechanisms underlying these benefits are largely unknown. We studied how leukocytapheresis mobilizes bone marrow cells into the peripheral circulation in patients with active UC. Leukocytapheresis transiently reduced peripheral leukocytes, followed by an overshoot increase with emergence of immature leukocytes. The numbers of colonies and CD34(+) cells were comparable between UC patients and normal controls. Shortly after leukocytapheresis, the numbers of both colonies and CD34(+) cells increased significantly in UC patients (P < 0.0001 and P = 0.0372, respectively). This was not associated with changes in the concentration of circulating cytokines or epinephrine. These results indicate that leukocytapheresis mobilizes bone marrow cells into the circulation. This cell replacement may partly explain the therapeutic benefit in UC. The functional role of the mobilized bone marrow cells in affected intestine remains to be characterized.

show abstract

mentioning

confidence: 99%

Mobilization of Bone Marrow Cells by Leukocytapheresis in Patients With Ulcerative Colitis

et al. 2008

View full text Add to dashboard Cite

show abstract

“…We found that LCAP efficiently removed activated mononuclear leucocytes from the circulation, and that the repopulating cells showed reduced activation status. These findings may partly explain the previously demonstrated clinical benefits of LCAP [16][17][18][19].…”

Section: Introductionmentioning

confidence: 58%

“…Summarizing results of previous clinical reports, Ortolano et al . [16] concluded that 76% of 115 patients with inflammatory bowel disease treated with LCAP showed remission that did not require corticosteroid or cytoablative support for maintenance. More recently, Sawada et al .…”

Section: Introductionmentioning

confidence: 99%

Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis

Mitsuyama¹,

Suzuki²,

Matsumoto³

et al. 2005

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryInfiltration by circulating inflammatory cells is a prominent local inflammatory feature of ulcerative colitis (UC). Several trials have suggested that leukocytapheresis by filtration can benefit patients with active UC. We investigated how this therapy might modulate the inflammatory response. Patients with active UC who were beginning repeated filtration leukocytapheresis were studied. Mononuclear cell preparations were obtained from blood before and after the first treatment, and expression of cytokine signalling components and the cell-proliferative response were analysed in vitro . Leukocytapheresis reduced lipopolysaccharide-induced production of proinflammatory cytokines (interleukin-1, -6, -8 and tumour necrosis factor-a a a a , P < < < < 0·05 for all) and activation of intracellular signalling components (nuclear factor-k k k k B, mitogen-activated protein kinases, and signal transducer and activator of transcription-3), as well as surface expression of toll-like receptor-4 ( P < < < < 0·05) in mononuclear cells. The therapy also reduced the cell-proliferative response by mononuclear cells stimulated with sonicated bacterial preparations from autologous intestine ( P < < < < 0·05). These results indicate that activated mononuclear cells in the peripheral blood of patients with active UC are removed by leukocytapheresis and replaced by cells with a lower activation status. This replacement may partly explain the therapeutic benefit.

show abstract

“…Leukocyte removal therapy has been proposed as a non‐pharmacological treatment; it involves the removal of activated leukocytes by apheresis and has the potential to improve bowel inflammation in UC . Cellsorba (Asahi Medical Co. Ltd, Tokyo, Japan) is a leukocyte apheresis device filled with very fine polyester fiber, and it removes lymphocytes in addition to granulocytes and monocytes (leukocytapheresis [LCAP]) …”

Section: Introductionmentioning

confidence: 99%

Caudal type homeobox 2 expression induced by leukocytapheresis might be associated with mucosal healing in ulcerative colitis

Tsuchiya

Hayashi

Fukushima

et al. 2017

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

A Review of Leukofiltration Therapy for Decreasing the Morbidity Associated with Cardiopulmonary Bypass and Acute Inflammatory Bowel Disease

Cited by 7 publications

References 69 publications

Mobilization of Bone Marrow Cells by Leukocytapheresis in Patients With Ulcerative Colitis

Mobilization of Bone Marrow Cells by Leukocytapheresis in Patients With Ulcerative Colitis

Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis

Caudal type homeobox 2 expression induced by leukocytapheresis might be associated with mucosal healing in ulcerative colitis

Contact Info

Product

Resources

About